AI-Driven Drug Development Accelerates with Insilico Medicine's Phase 3 Trials
AI reduces preclinical phases to 12–18 months, cutting drug development costs.
GENESIS-IPF trial showed 60 mg QD group gained +98.4 mL in FVC.
Insilico discusses regulatory approvals and has $100M Eli Lilly deal.
HK IPO raised $293M to support global expansion.
VCs invested $2.7B in AI drug startups by Q3 2025.